CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Restructuring and Related Cost, Incurred Cost
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Restructuring and Related Cost, Incurred Cost of $9.04 million for the 3-month period ending 2024-03-30, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostIncurredCost · last filed 2024-05-09
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring and related cost, incurred cost for the quarter ending 2024-03-30 was $9.04M, a 888.73% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring and related cost, incurred cost for the quarter ending 2023-04-01 was $914.00K.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring and related cost, incurred cost for the quarter ending 2021-12-25 was $1.85M, a 38.18% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring and related cost, incurred cost for the quarter ending 2021-09-25 was $1.48M, a 38.73% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring and related cost, incurred cost for fiscal 2023 was $11.54M, a 71.41% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring and related cost, incurred cost for fiscal 2022 was $6.73M, a 18.21% increase from fiscal 2021.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring and related cost, incurred cost for fiscal 2021 was $5.70M, a 38.66% decline from fiscal 2020.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring and related cost, incurred cost for fiscal 2020 was $9.28M, a 26.75% decline from fiscal 2019.
| Period end | Restructuring and Related Cost, Incurred Cost 3 month | Restructuring and Related Cost, Incurred Cost 6 month | Restructuring and Related Cost, Incurred Cost 9 month | Restructuring and Related Cost, Incurred Cost 12 month |
|---|---|---|---|---|
| 2024-03-30 | $9.04M 10-Q · filed 2024-05-09 | |||
| 2023-12-30 | $11.54M 10-K · filed 2024-02-14 | |||
| 2023-04-01 | $914.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $6.73M 10-K · filed 2024-02-14 | |||
| 2021-12-25 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $3.34M derived: sum of 2 quarters · filed 2024-02-14 | $4.95M derived: sum of 3 quarters · filed 2024-02-14 | $5.70M 10-K · filed 2024-02-14 |
| 2021-09-25 | $1.48M 10-Q · filed 2021-11-03 | $3.09M derived: sum of 2 quarters · filed 2021-11-03 | $3.84M 10-Q · filed 2021-11-03 | $5.18M derived: sum of 4 quarters · filed 2022-02-16 |
| 2021-06-26 | $1.61M 10-Q · filed 2021-08-04 | $2.36M 10-Q · filed 2021-08-04 | $3.70M derived: sum of 3 quarters · filed 2022-02-16 | $4.77M derived: sum of 4 quarters · filed 2022-02-16 |
| 2021-03-27 | $749.00K 10-Q · filed 2021-05-04 | $2.09M derived: sum of 2 quarters · filed 2022-02-16 | $3.16M derived: sum of 3 quarters · filed 2022-02-16 | $9.52M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-12-26 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $2.41M derived: sum of 2 quarters · filed 2022-02-16 | $8.77M derived: sum of 3 quarters · filed 2022-02-16 | $9.28M 10-K · filed 2022-02-16 |
| 2020-09-26 | $1.07M 10-Q · filed 2021-11-03 | $7.43M derived: sum of 2 quarters · filed 2021-11-03 | $7.94M 10-Q · filed 2021-11-03 | $15.11M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-06-27 | $6.36M 10-Q · filed 2021-08-04 | $6.87M 10-Q · filed 2021-08-04 | $14.04M derived: sum of 3 quarters · filed 2022-02-16 | $16.69M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-03-28 | $517.00K 10-Q · filed 2021-05-04 | $7.68M derived: sum of 2 quarters · filed 2022-02-16 | $10.34M derived: sum of 3 quarters · filed 2022-02-16 | $11.95M derived: sum of 4 quarters · filed 2022-02-16 |
| 2019-12-28 | $7.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $9.82M derived: sum of 2 quarters · filed 2022-02-16 | $11.43M derived: sum of 3 quarters · filed 2022-02-16 | $12.67M 10-K · filed 2022-02-16 |
| 2019-09-28 | $2.65M 10-Q · filed 2020-10-29 | $4.26M derived: sum of 2 quarters · filed 2020-10-29 | $5.51M 10-Q · filed 2020-10-29 | $6.26M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-06-29 | $1.61M 10-Q · filed 2020-08-05 | $2.85M 10-Q · filed 2020-08-05 | $3.61M derived: sum of 3 quarters · filed 2021-02-17 | $8.32M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-03-30 | $1.25M 10-Q · filed 2020-05-07 | $2.00M derived: sum of 2 quarters · filed 2021-02-17 | $6.71M derived: sum of 3 quarters · filed 2021-02-17 | $8.79M derived: sum of 4 quarters · filed 2021-02-17 |
| 2018-12-29 | $752.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $5.47M derived: sum of 2 quarters · filed 2021-02-17 | $7.54M derived: sum of 3 quarters · filed 2021-02-17 | $8.68M 10-K · filed 2021-02-17 |
| 2018-09-29 | $4.71M 10-Q · filed 2019-11-06 | $6.79M derived: sum of 2 quarters · filed 2019-11-06 | $7.93M 10-Q · filed 2019-11-06 | $10.23M derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-06-30 | $2.08M 10-Q · filed 2019-07-31 | $3.21M 10-Q · filed 2019-07-31 | $5.52M derived: sum of 3 quarters · filed 2020-02-11 | $6.15M derived: sum of 4 quarters · filed 2020-02-11 |
| 2018-03-31 | $1.14M 10-Q · filed 2019-05-07 | $3.44M derived: sum of 2 quarters · filed 2020-02-11 | $4.08M derived: sum of 3 quarters · filed 2020-02-11 | $4.40M derived: sum of 4 quarters · filed 2020-02-11 |
| 2017-12-30 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-11 | $2.94M derived: sum of 2 quarters · filed 2020-02-11 | $3.26M derived: sum of 3 quarters · filed 2020-02-11 | $4.28M 10-K · filed 2020-02-11 |
| 2017-09-30 | $636.00K 10-Q · filed 2018-11-07 | $959.00K derived: sum of 2 quarters · filed 2018-11-07 | $1.98M 10-Q · filed 2018-11-07 | |
| 2017-07-01 | $323.00K 10-Q · filed 2018-08-08 | $1.34M 10-Q · filed 2018-08-08 | ||
| 2017-04-01 | $1.02M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $13.07M 10-K · filed 2019-02-13 | |||
| 2015-12-26 | $6.17M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |